Arcellx stock (NASDAQ: ACLX) climbed roughly 80% in premarket trade on Monday after Gilead Sciences agreed to buy the cancer-therapy developer in a $7.8 billion all-cash deal. The stock’s move wasn’t a mystery rally. The surge was a classic takeover repricing: once Gilead and Arcellx signed a definitive deal at $115 a share, traders quickly
South Korea’s stablecoin framework is facing renewed scrutiny as the country’s central bank urges lawmakers to keep control of won-pegged digital tokens within the traditional banking system. In a report submitted to the Bank of Korea’s parliamentary oversight body, the central bank raised concerns about privately issued stablecoins. It warned that such tokens could weaken
Finland’s IQM is positioning itself at the centre of Europe’s quantum technology ambitions as it prepares to enter public markets in the US. According to a CNBC report, the company said on Monday it plans to merge with Real Asset Acquisition Corp, a special purpose acquisition company, in a deal that would value IQM at
Blue Owl stock price has crashed in the past few months, turning one of the most blue-chip financial giants into a fallen angel. It dropped to a low of $10.50 on Friday, down sharply from the all-time high of $25.20. This retreat has brought its market capitalization to $15.4 billion from a record high of
Fridays used to be reserved for routine headlines. But since Donald Trump’s reelection, every Friday seems like a bombshell day. And last Friday delivered a constitutional jolt to global trade. In a 6–3 ruling, the US Supreme Court struck down President Donald Trump’s use of emergency powers to impose sweeping tariffs, removing the executive “on-off
Merck said on Monday that it will split its human-health operations into two separate divisions, a move designed to sharpen focus across its portfolio and ensure smoother launches of new medicines. The move comes as the drugmaker seeks to prepare for mounting sales pressure later this decade, driven by the looming loss of exclusivity for
Royal Bank of Canada stock has been in an unstoppable bull run in the past few years and is now hovering at its all-time high. It has soared by 160% in the last five years, beating JPMorgan, which has jumped by over 133% in the same period. So, will the rally accelerate as the company
Millions of people on GLP-1 weight-loss drugs know the weekly routine by heart: a new injector pen, a new box, another reminder to refill, and one more item for the sharps bin. Eli Lilly is trying to make that routine feel less like a chore. The company says it has launched a new Zepbound KwikPen
US equities were little changed on Monday after President Donald Trump announced an increase in global tariffs to 15%, following a Supreme Court ruling that struck down his earlier “reciprocal” tariff framework. The S&P 500 hovered around the flatline during the session, while the Dow Jones Industrial Average and the Nasdaq Composite also traded with
Almirall, a pharmaceutical firm based in Spain, ended 2025 with a net profit of €46.2 million, which was 357% more than its 2024 profit of €10.1 million. The Barcelona-based pharmaceutical company was able to exceed the significant €1 billion sales threshold thanks to a 12.5% increase in revenue to €1.1145 billion. Following a more muted